Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
C274682-1mg | 1mg | In stock | $9.90 | |
C274682-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $13.90 | |
C274682-25mg | 25mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $27.90 | |
C274682-100mg | 100mg | In stock | $91.90 | |
C274682-250mg | 250mg | In stock | $154.90 | |
C274682-1g | 1g | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $400.90 |
Cell-permeable, competitive, selective, potent p300/CBP HAT inhibitor
Synonyms | 328968-36-1|C646|4-[(4Z)-4-[[5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid|C 646|4-(4-((5-(4,5-Dimethyl-2-nitrophenyl)furan-2-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid|4-[(4E)-4-[ |
---|---|
Specifications & Purity | 98% |
Storage Temp | Store at -20°C,Argon charged,Desiccated |
Shipped In | Dry ice |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of E1A binding protein p300 |
Product Description | C646 was used to study the role of p300 in chronic neuropathic pain in rats with chronic constriction injury. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 4-[(4Z)-4-[[5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid |
---|---|
INCHI | InChI=1S/C24H19N3O6/c1-13-10-20(21(27(31)32)11-14(13)2)22-9-8-18(33-22)12-19-15(3)25-26(23(19)28)17-6-4-16(5-7-17)24(29)30/h4-12H,1-3H3,(H,29,30)/b19-12- |
InChi Key | HEKJYZZSCQBJGB-UNOMPAQXSA-N |
Canonical SMILES | CC1=CC(=C(C=C1C)[N+](=O)[O-])C2=CC=C(O2)C=C3C(=NN(C3=O)C4=CC=C(C=C4)C(=O)O)C |
Isomeric SMILES | CC1=CC(=C(C=C1C)[N+](=O)[O-])C2=CC=C(O2)/C=C\3/C(=NN(C3=O)C4=CC=C(C=C4)C(=O)O)C |
PubChem CID | 1285941 |
Molecular Weight | 445.42 |
PubChem CID | 1285941 |
---|---|
CAS Registry No. | 328968-36-1 |
ChEMBL Ligand | CHEMBL1797936 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
L2123473 | Certificate of Analysis | Oct 20, 2022 | C274682 |
L2123474 | Certificate of Analysis | Oct 20, 2022 | C274682 |
L2123475 | Certificate of Analysis | Oct 20, 2022 | C274682 |
L2123476 | Certificate of Analysis | Oct 20, 2022 | C274682 |
L2123071 | Certificate of Analysis | Oct 20, 2022 | C274682 |
L2123072 | Certificate of Analysis | Oct 20, 2022 | C274682 |
Solubility | Soluble in DMSO to 25 mM |
---|
1. Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, Holbert MA, Crump NT, Hazzalin CA, Liszczak G, Yuan H et al.. (2010) Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.. Chem Biol, 17 (5): (471-82). [PMID:20534345] |
2. Dekker FJ, van den Bosch T, Martin NI. (2014) Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases.. Drug Discov Today, 19 (5): (654-660). [PMID:24269836] |
3. van den Bosch T, Boichenko A, Leus NGJ, Ourailidou ME, Wapenaar H, Rotili D, Mai A, Imhof A, Bischoff R, Haisma HJ et al.. (2016) The histone acetyltransferase p300 inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases.. Biochem Pharmacol, 102 (3): (130-140). [PMID:26718586] |
4. Dahlin JL, Nelson KM, Strasser JM, Barsyte-Lovejoy D, Szewczyk MM, Organ S, Cuellar M, Singh G, Shrimp JH, Nguyen N et al.. (2017) Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors.. Nat Commun, 8 (1): (1527). [PMID:29142305] |
5. Sacta MA et al.. (2018) Gene-specific mechanisms direct glucocorticoid-receptor-driven repression of inflammatory response genes in macrophages.. Elife, 7 [PMID:29424686] |
6. Butcher NJ et al.. (2020) Modulation of Human Arylamine N-Acetyltransferase 1 Activity by Lysine Acetylation: Role of p300/CREB-Binding Protein and Sirtuins 1 and 2.. Mol Pharmacol, 98 (2): (88-95). [PMID:32487734] |
7. Fischer A et al.. (2017) Membrane localization of acetylated CNK1 mediates a positive feedback on RAF/ERK signaling.. Sci Adv, 3 (8): (e1700475). [PMID:28819643] |
8. Bandyopadhaya A et al.. (2017) NF-?Bp50 and HDAC1 Interaction Is Implicated in the Host Tolerance to Infection Mediated by the Bacterial Quorum Sensing Signal 2-Aminoacetophenone.. Front Microbiol, 8 (1211). [PMID:28713342] |
9. Hao Y et al.. (2022) p300 arrests intervertebral disc degeneration by regulating the FOXO3/Sirt1/Wnt/β-catenin axis.. Aging Cell, 21 (8): (e13677). [PMID:35907249] |
10. Wei L et al.. (2019) Silencing of lncRNA MALAT1 Prevents Inflammatory Injury after Lung Transplant Ischemia-Reperfusion by Downregulation of IL-8 via p300.. Mol Ther Nucleic Acids, 18 (285-297). [PMID:31604167] |
11. Smith ER et al.. (2019) TGF-ß1 modifies histone acetylation and acetyl-coenzyme A metabolism in renal myofibroblasts.. Am J Physiol Renal Physiol, [PMID:30623724] |
12. Peghaire C et al.. (2019) The transcription factor ERG regulates a low shear stress-induced anti-thrombotic pathway in the microvasculature.. Nat Commun, 10 (5014). [PMID:31676784] |